Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Thu, 15 Oct 2026 16:05:00 -0400

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.

Presentation Details

Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10th Annual Healthcare Conference to be held in New York City, on October 20th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.

Presentation Details

Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero’s Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employees in accordance

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:05:00 -0400

CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero’s Board of Directors approved grants, made on October 1, 2026, of an aggregate of 233,000 restricted stock unit awards (RSUs) and 323,000 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The stock options and RSUs are being granted as an inducement material to Spero’s new employees in accordance

Spero Therapeutics (SPRO) PT Raised to $6 at H.C. Wainwright

Mon, 14 Sep 2026 06:56:25 -0400

H.C. Wainwright analyst Raghuam Selvaraju raised the price target on Spero Therapeutics (NASDAQ: SPRO) to $6.00 (from $5.00) while maintaining a Buy rating.

The analyst comments "Resetting around an in-licensed I&I asset—raising price target. In mid-July 2026, Spero Therapeutics announced an exclusive license agreement on IBI355 (Spero R&D code: SP001), a third-generation Fc-silent anti-CD40L antibody, from Innovent Biologics (1801.HK; not rated), a publicly-traded, China-based biotechnology company. Spero holds exclusive rights to develop, research, manufacture, and commercialize IBI355 worldwide, excluding Greater China, where Innovent retains rights. Currently, Spero expects to advance IBI355 into a Phase 2 study in IgG4-related disease (IgG4-RD) patients

Spero Therapeutics (SPRO) PT Raised to $6 at H.C. Wainwright

Mon, 14 Sep 2026 06:56:25 -0400

H.C. Wainwright analyst Raghuam Selvaraju raised the price target on Spero Therapeutics (NASDAQ: SPRO) to $6.00 (from $5.00) while maintaining a Buy rating.

Form EFFECT Spero Therapeutics, Inc.

Fri, 11 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260911/27050465.html

Form 8-K Spero Therapeutics, Inc. For: Aug 28

Fri, 28 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260828/26999170.html

Form 8-K Spero Therapeutics, Inc. For: Aug 28

Fri, 28 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260828/26999170.html

Form S-3 Spero Therapeutics, Inc.

Fri, 28 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260828/26998952.html

Form S-3 Spero Therapeutics, Inc.

Fri, 28 Aug 2026 17:04:00 -0400

si-local-file:///var/storage/secattach/20260828/26998952.html

SmartPros Ltd. (SPRO) Tops Q2 EPS by 1c

Wed, 12 Aug 2026 16:41:03 -0400

SmartPros Ltd. (NASDAQ: SPRO) reported Q2 EPS of ($0.16), $0.01 better than the analyst estimate of ($0.17).

For earnings history and earnings-related data on SmartPros Ltd. (SPRO) click here.

Form 8-K Spero Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26912899.html

Form 8-K Spero Therapeutics, Inc. For: Aug 12

Wed, 12 Aug 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260812/26912899.html

Form 10-Q Spero Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26912640.html

Form 10-Q Spero Therapeutics, Inc. For: Jun 30

Wed, 12 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260812/26912640.html

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update